First Trust Advisors’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
KCM
First Trust Advisors's VRDN Position: Q3 2026 in Review
First Trust Advisors increased its Viridian Therapeutics (VRDN) stake by 2.9% in Q3 2026, buying an estimated $114K and bringing the position to 186,552 shares worth $3.84M. The position accounts for ﹤0.01% of the portfolio, ranked #1726.
First Trust Advisors first reported a position in VRDN in Q2 2023 and has held it in 5 quarters since. The position peaked at $5.9M in Q1 2026. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- First Trust Advisors held 186,552 shares of Viridian Therapeutics worth $3.84M as of Q3 2026.
- First Trust Advisors bought 5,318 Viridian Therapeutics shares in Q3 2026, an estimated $114K.
- Viridian Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q3 2026, its #1726 holding.
- First Trust Advisors first reported a position in Viridian Therapeutics in Q2 2023 and has held it in 5 quarters since.
- First Trust Advisors's Viridian Therapeutics position peaked at $5.9M in Q1 2026.
- 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on First Trust Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.